Auxilium Pharmaceuticals — Investor Presentation (May 2009)
44 slides from Auxilium Pharmaceuticals's investor presentation, May 13, 2009
Slide 1: May 2009 Exhibit 99.1
May 2009 Exhibit 99.1 (NASDAQ: AUXL)
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,
Slide 3: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories
Slide 4: Anticipated XIAFLEX Events 2009-2010
• FDA Approval In Dupuytren’s Contracture (PDUFA August 28, 2009) • 12 month Dupuytren's Contracture safety presentation at medical conference • Publication of CORD I data in top - tier medical journal • U.S. Dupuytren’s Contracture Launch (~ 60 days post-approval) • Top-line results of Peyronie's P
Slide 5: Pipeline Continues to Advance
Pipeline Continues to Advance TESTIM ® GEL XIAFLEX™ XIAFLEX™ XIAFLEX™ Transmucosal Film AA4010 Transmucosal Film Transmucosal Film Hormone & Urology Note: Seeking partners for Transmucosal film product candidates PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuy
Slide 6: Strong Strategic Partner for XIAFLEX in EU Validates Market Potential
Strong Strategic Partner for XIAFLEX in EU Validates Market Potential • Compelling economics for Auxilium: • Up-front payment of $75 million • $150 million tied to regulatory milestones • $260 million based on sales milestones • Significant increasing tiered royalties based on sales of XIAFLEX in Pf
Slide 7: XIAFLEX Driver of Long-Term Growth
XIAFLEX Driver of Long-Term Growth XIAFLEX product and packaging have not been approved by the FDA
Slide 8: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • State of the art biological manufacturing facility • Worldwide rights gener
Slide 9: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery may be rese
Slide 10: Current Treatment Options Require Invasive Surgery or Are Unapproved
Current Treatment Options Require Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Non-surgical options > Splinting > Physical therapy > Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation
Slide 11: XIAFLEX Offers an Improved Mechanism of Action
XIAFLEX Offers an Improved Mechanism of Action • Clostridial collagenase is faster and more potent than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases in the product End products Fast cleavage Human collagenase Human collagenase (MMP) (MMP) Slow clea
Slide 12: CORD I - Largest Double-blind, Placebo-controlled Trial in Dupuytren's Contracture
CORD I - Largest Double-blind, Placebo- controlled Trial in Dupuytren’s Contracture • Primary endpoint is reduction in contracture to within - 5 8 of normal > randomized in 2:1 ratio of active to placebo > enrolled a 2:1 ratio of MP:PIP > enrolled 1:1 ratio of less severe to more severe joints • Sec
Slide 13: PANY
49.1 50.2 847% 3 — | SG — | PANY [—_ — | saeshieg quauranoiduyy yA (%) Wed. 3% ll 64% (%) ssazang yyy juaaiag Innovations for tite”
Slide 14: XIAFLEX Phase III AE and SAE Rates Compare to Surgical Complications
XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications Tendon / Ligament: Confirmed Tendon Rupture 3 0.12% Ligament Injury 1 0.04% Total Tendon / Ligament 4 0.15% Deep Vein Thrombosis 1 0.04% Dupuytren’s Disease 1 0.04% Complex Regional Pain Syndrome 1 0.04% Total 7 0.
Slide 15: XIAFLEX Offers a Non-Invasive Treatment for Dupuytren's Contracture
XIAFLEX Offers a Non-Invasive Treatment for Dupuytren’s Contracture
Slide 16: XIAFLEX for Dupuytren's Contracture Key Clinical Takeaways
XIAFLEX for Dupuytren’s Contracture Key Clinical Takeaways • Efficacy should compare favorably to surgery – Primary endpoint of 5° reached with statistical significance in multiple studies – Secondary endpoints support commercial uptake • Less severe contractures responded better than more severe co
Slide 17: XIAFLEX I.P. Position for Dupuytren's Contracture
XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug granted on May 23, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity expected in EU for 10 years post-approval > Data protection granted for 8 years • Method of Use Patent in U.S. through 2014 • Use Patent in
Slide 18: XIAFLEX Supply Chain
XIAFLEX Supply Chain • API produced in Horsham, PA – - 8 C storage expected at launch – Annual capacity at current yield should be sufficient for several years of global launch expectations – 1 manufacturing train in use and validated; capacity to expand for future demand • Fill and Lyophilization:
Slide 19: Dupuytren's Contracture – an Unmet Medical Need
Dupuytren’s Contracture –an Unmet Medical Need Tubiana 2006. Hueston Skoog Mikkelsen • Disease prevalence is estimated at 3%-6% of adult Caucasian population, or 13.5 to Million, in U.S. and EU, but occurs in all populations • Higher prevalence in patients of northern-European descent • Hereditary c
Slide 20: Extensive Market Research Performed with Dupuytren's Surgeons
Extensive Market Research Performed with Dupuytren’s Surgeons • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571 Orthopedic Surgeo
Slide 21: Annually, >240,000 Dupuytren's Candidates Could Exist between U.S. & EU
Annually, >240,000 Dupuytren’s Candidates Could Exist between U.S. & EU Source: 2006 Auxilium research and analysis
Slide 22: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated
Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence – Based on literature, ~ 13.5M to 27M patients in U.S. and EU, however only ~1M patients annually seeking treatment in U.S. and EU • Sustainable patient pool – New patients within an ageing population •
Slide 23: Peyronie's Disease is a Devastating Disorder
Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670-678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/ d
Slide 24: Peyronie's Disease - an Unmet Medical Need
Peyronie’s Disease - an Unmet Medical Need Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: 2350 - 2353;Rhoden et al: Int J. Impot Res 2001 :13 : 291 - 293; La Pera et al : EUR Urology 2001: 40 :525 - 530. Smith
Slide 25: Current Surgical Options - Treatment of Last Resort
Current Surgical Options- Treatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated to att
Slide 26: Unapproved Treatments for Peyronie's Disease Have Been Used With Little Success
Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a
Slide 27: Study 1030 Study 1035
Study 1030 Study 1035 100% 100% 89% :, L c r L. & B say [ L fo 5 53% heen € r L o 2 ie 35% = . o o L le ' rs - F ‘| Month 3 Month 6 Month 9 Week6 Month3 Month6 Months a Innovations for tite”
Slide 28: Peyronie's Phase IIb Study Top-line Data Expected in 4Q09
Peyronie’s Phase IIb Study Top-line Data Expected in 4Q09 • Study designed to assess the safety and efficacy with XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – 12 U.S. sites • Patients must be able to maintain a ri
Slide 29: Peyronie's Phase IIb Study Design
Peyronie’s Phase IIb Study Design A XIAFLEX yes 45 B Placebo yes 15 C XIAFLEX no 45 D Placebo no 15 120 Arm Study Drug Plaque Modeling Targeted Number of Patients • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling.
Slide 30: Peyronie's Phase IIb Trial Utilizes a Novel Patient Reported Outcome
Peyronie’s Phase IIb Trial Utilizes a Novel Patient Reported Outcome (PRO) • Study is designed to validate Auxilium’s proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week period: – penile pain – Peyro
Slide 31: Extensive Market Research Performed with Peyronie's Surgeons
Extensive Market Research Performed with Peyronie’s Surgeons • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given fe
Slide 32: Annually, >210,000 Peyronie's Candidates Could Exist between U.S. and Europe
Annually, >210,000 Peyronie’s Candidates Could Exist between U.S. and Europe Source: 2006 Auxilium research and analysis
Slide 33: XIAFLEX I.P. Position for Peyronie's Disease
XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug granted on March 12, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication • Method of Use Patent in U.S. through 2019 • Use Patent Granted in F
Slide 34: Testim 1% Testosterone Gel: Near-Term Growth Driver
Testim ® 1% Testosterone Gel: Near-Term Growth Driver
Slide 35: Testim Maintains Double-Digit Growth in Testosterone Replacement Therapy Market
Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonad
Slide 36: 447% +30%
447% +30%
Slide 37: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $200 $287 $340 $383 $449 $690 $563 $49 $59 $77 $118 $210 $302 $399 $459 $499 $568 $685 $819 Gel Patch Oral Injectables ($ in millions) Gel Segment Growth ($) Mar 2009 L12M: 26.7%
Slide 38: Testim Quarterly Net Revenues and Scripts Continuing Track Record of Consistent Revenue Growth
Testim® Quarterly Net Revenues and Scripts Continuing Track Record of Consistent Revenue Growth ($ in millions) 1Q09 Net Testim Revenues Y/Y Growth: +24.7% 1Q09 TRX Y/Y Growth: +14.1% Source: Auxilium and IMS data $42.8M $68.9M $95.7M $125.1M $33.8M
Slide 39: Testim Patent Coverage
Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • Divisional application and continuations filed with U.S. PTO in late 2007 with a plan t
Slide 40: Q1 '09 Financial Results and 2009 Guidance
Revenues $34.7 $27.1 $150-155 R&D Expense $13.5 $13.2 $45-50 SG&A Expense $26.4 $21.0 $120-130 Net Loss ($13.2) ($12.3) ($55-60) Stock – Based Comp Expense $4.5 $2.1 $16-19 Cash & Cash Equivalents $90.2 Q1 ‘09 Financial Results and 2009 Guidance ($ Millions) Q1 ’09 Q1 ‘08 Guidance Currently approxim
Slide 41: Strategic Priorities in 2009
Strategic Priorities in 2009 • Continue our pre - launch commercialization efforts and be prepared to launch in ~60 days after anticipated approval date of August 28, 2009; • Release top-line data from the XIAFLEX Peyronie’s disease Phase IIb trial, which we anticipate in 4Q09; • Work diligently wit
Slide 42: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories
Slide 43: Management Contact
Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 jfickenscher@auxilium.com William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 wsargent@auxilium.com
Slide 44: May 2009
May 2009 (NASDAQ: AUXL)
Auxilium Pharmaceuticals — Investor Presentation (May 2009) on 6ix